Schizophrenia

Lumateperone (Caplyta) is used for the treatment of schizophrenia and bipolar depression.

New study results focus on blood pressure, blood sugar, and cholesterol levels; body mass index; and smoking status when individuals have bipolar or schizoaffective disorder or schizophrenia.

The agency previously granted a priority review for the supplemental new drug application and also approved the drug in 2015 to treat adults.

Ten quiz questions to assess your knowledge on common symptoms and treatments for schizophrenia.

Prevalence of type 2 diabetes has been found higher in people with bipolar disorder, schizophrenia, and major depression compared to the general population.

Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were similar between lumateperone and placebo.

The trial randomized patients to receive TV-46000 once monthly, TV-46000 once every 2 months, or placebo, and found that patients had improved outcomes on TV-46000 regardless of dosing schedule.